Sign In
Last checked at 
17 Feb 2022 16:00
GlaxoSmithKline plc (the 'Company' and 'GSK')
Vesting of Awards under the GSK Deferred Investment Award programme
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') of awards made in 2019 to under the GlaxoSmithKline Deferred Investment Award programme (the 'Programme'). The awards, which were conditional on continued employment with the GlaxoSmithKline group, vested on 14 February 2022.
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Following the vesting on 14 February 2022 of an award made on 3 September 2019 under the GlaxoSmithKline Deferred Investment Award programme, Ms Conrad will receive a cash payment of £157,905.60 less applicable tax withholding in respect of 10,050 notional ordinary shares.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 | 10,050 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-14 | |||
f) | Place of the transaction
| N/A | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Jackson | |||
b) | Position/status | SVP, Global Communication and CEO Office | |||
c) | Initial notification/ amendment | Initial Notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |||
b) | Nature of the transaction | Following the vesting on 14 February 2022 of an award made on 3 September 2019 under the GlaxoSmithKline Deferred Investment Award programme, Ms Jackson will receive a cash payment of £157,905.60 less applicable tax withholding in respect of 10,050 notional ordinary shares.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £15.712 | 10,050 |
| ||
|
|
|
| ||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2022-02-14 | |||
f) | Place of the transaction
| N/A | |||
Follow the stocks
